Mizuho Securities USA LLC Lowers Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Mizuho Securities USA LLC has reduced its stake in Intuitive Surgical (NASDAQ:ISRG) by 15.4%, selling 5,201 shares to hold a total of 28,557 shares valued at approximately $14.14 million.
• Intuitive Surgical reported strong quarterly earnings with an EPS of $2.19, exceeding analyst expectations, alongside a revenue of $2.44 billion, reflecting a year-over-year increase of 21.4%.
• Analysts are generally positive on Intuitive Surgical's prospects, with a consensus rating of "Moderate Buy" and an average price target of $595.95, suggesting potential for upward movement in the stock price.

Mizuho Securities USA LLC trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,557 shares of the medical equipment provider's stock after selling 5,201 shares during the quarter. Mizuho Securities USA LLC's holdings in Intuitive Surgical were worth $14,143,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ISRG. Chilton Capital Management LLC lifted its holdings in Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Parvin Asset Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $26,000. Global Financial Private Client LLC lifted its holdings in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the last quarter. Elite Financial Inc. acquired a new position in Intuitive Surgical in the 1st quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA acquired a new position in Intuitive Surgical in the 1st quarter valued at $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Trading Up 0.4%

ISRG stock traded up $1.77 during trading on Monday, reaching $471.85. 1,418,064 shares of the stock were exchanged, compared to its average volume of 2,244,672. The firm's 50 day moving average is $514.89 and its 200 day moving average is $527.45. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The firm has a market cap of $169.15 billion, a P/E ratio of 65.81, a price-to-earnings-growth ratio of 4.93 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company's quarterly revenue was up 21.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.78 earnings per share. As a group, analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of the stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at approximately $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary S. Guthart sold 7,893 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $498.64, for a total value of $3,935,765.52. Following the transaction, the insider directly owned 13,187 shares of the company's stock, valued at approximately $6,575,565.68. This trade represents a 37.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,881 shares of company stock valued at $7,920,634. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ISRG shares. Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Wells Fargo & Company boosted their price target on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their price target for the stock from $515.00 to $440.00 in a report on Monday, June 9th. BTIG Research boosted their price target on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Truist Financial boosted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.